Brian Stephenson Purchases 9,391 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 9,391 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was bought at an average cost of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This trade represents a 53.93% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $22.87 on Friday. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76. The stock has a market cap of $30.65 million, a P/E ratio of -0.16 and a beta of -0.25.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on FTH. Weiss Ratings began coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. HC Wainwright initiated coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday. They issued an “outperform” rating and a $57.00 price objective for the company. Finally, BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.